{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:41Z","timestamp":1761870341913,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.clml.2011.10.001","type":"journal-article","created":{"date-parts":[[2011,12,2]],"date-time":"2011-12-02T05:08:55Z","timestamp":1322802535000},"page":"12-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Considerations in the Management of Elderly Patients With Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"12","author":[{"given":"Karen","family":"Seiter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.10.001_bib1","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2011.10.001_bib2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.10.001_bib3","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph' translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.10.001_bib4","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780","article-title":"Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow","volume":"92","author":"Pear","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.001_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2009.07.007","article-title":"Epidemiology of chronic myeloid leukaemia (CML)","volume":"22","author":"Rohrbacher","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"author":"Altekruse","key":"10.1016\/j.clml.2011.10.001_bib6"},{"key":"10.1016\/j.clml.2011.10.001_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM197902153000702","article-title":"Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin","volume":"300","author":"Fefer","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.001_bib8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood.V62.3.689.689","article-title":"Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia","volume":"62","author":"Talpaz","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.001_bib9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","article-title":"Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.001_bib10","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","article-title":"UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response","volume":"345","author":"Allan","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.10.001_bib12","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.001_bib13","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/sj.leu.2403821","article-title":"A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors","volume":"19","author":"Robin","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.10.001_bib14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.001_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2011.10.001_bib16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2009-0198","article-title":"How does older age influence oncologists' cancer management?","volume":"15","author":"Foster","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2011.10.001_bib17","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.2006.10.4208","article-title":"Older female cancer patients: importance, causes, and consequences of undertreatment","volume":"25","author":"Bouchardy","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.001_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2010.03.018","article-title":"Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia","volume":"123","author":"Wiggins","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2011.10.001_bib19","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"Bjorkholm","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.001_bib20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.001_bib21","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/00007611-198710000-00007","article-title":"Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia","volume":"80","author":"Kantarjian","year":"1987","journal-title":"South Med J"},{"key":"10.1016\/j.clml.2011.10.001_bib22","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2011.10.001_bib23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/cncr.11629","article-title":"Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"98","author":"Cortes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.10.001_bib24","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","article-title":"Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party","volume":"117","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.001_bib25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.leukres.2005.03.001","article-title":"Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment","volume":"29","author":"Latagliata","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2011.10.001_bib26","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.leukres.2011.05.015","article-title":"Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant\/intolerant to imatinib","volume":"35","author":"Latagliata","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2011.10.001_bib27","first-page":"1229","article-title":"Imatinib in very elderly CML patients: what can we achieve?","volume":"116","author":"Latagliata","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2011.10.001_bib28","first-page":"3286","article-title":"Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): a sub-analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) study","volume":"114","author":"le Coutre","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2011.10.001_bib29","first-page":"3233","article-title":"Nilotinib in elderly chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: efficacy and safety analysis","volume":"112","author":"Lipton","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2011.10.001_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.10239","article-title":"Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party","volume":"92","author":"Rosti","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.10.001_bib31","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.leukres.2011.01.017","article-title":"Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study","volume":"35","author":"Sanchez-Guijo","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2011.10.001_bib32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1179\/102453308X316004","article-title":"Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients","volume":"13","author":"Sheehy","year":"2008","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2011.10.001_bib33","doi-asserted-by":"crossref","unstructured":"Larson RA, Kim D, Rosti G, et al. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3-7, 2011; Chicago, IL.","DOI":"10.1200\/jco.2011.29.15_suppl.6511"},{"key":"10.1016\/j.clml.2011.10.001_bib34","first-page":"2293","article-title":"Low-dose dasatinib as front-line therapy for elderly (>60 years) patients with CML","volume":"116","author":"Porrini","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2011.10.001_bib35","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.001_bib36","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.001_bib37","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.001_bib38","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.001_bib39","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.001_bib40","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.001_bib41","doi-asserted-by":"crossref","first-page":"a2467","DOI":"10.1136\/bmj.a2467","article-title":"Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study","volume":"337","author":"Driver","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2011.10.001_bib42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1513\/pats.200508-081JS","article-title":"Aging","volume":"2","author":"Meyer","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.clml.2011.10.001_bib43","first-page":"3411","article-title":"Therapy with imatinib in elderly CML patients (>65 years): results of the German CML-Study IV","volume":"116","author":"Saussele","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"year":"2010","series-title":"Tasigna\u00ae (nilotinib) [prescribing information]","key":"10.1016\/j.clml.2011.10.001_bib44"},{"key":"10.1016\/j.clml.2011.10.001_bib45","first-page":"3421","article-title":"Safety and efficacy of dasatinib (DAS) vs. imatinib (IM) by baseline comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial","volume":"116","author":"Khoury","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"year":"2010","series-title":"Sprycel\u00ae (dasatinib) [prescribing information]","key":"10.1016\/j.clml.2011.10.001_bib46"},{"key":"10.1016\/j.clml.2011.10.001_bib47","first-page":"3430","article-title":"Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) with type 2 diabetes in the ENESTnd trial","volume":"116","author":"Saglio","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"first-page":"1","article-title":"Health, United States, 2010: With Special Feature on Death and Dying","year":"2011","key":"10.1016\/j.clml.2011.10.001_bib48"},{"key":"10.1016\/j.clml.2011.10.001_bib49","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"van Erp","year":"2009","journal-title":"Cancer Treat Rev"},{"year":"2010","series-title":"Gleevec\u00ae (imatinib mesylate)","key":"10.1016\/j.clml.2011.10.001_bib50"},{"issue":"21","key":"10.1016\/j.clml.2011.10.001_bib51","first-page":"3412","volume":"116","author":"Russo","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2011.10.001_bib53","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.beha.2009.10.001","article-title":"Response definitions and European LeukemiaNet management recommendations","volume":"22","author":"Baccarani","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2011.10.001_bib54","first-page":"1","article-title":"Deaths: final data for 2007","volume":"58","author":"Xu","year":"2010","journal-title":"Natl Vital Statistics Rep"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011005519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011005519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:04Z","timestamp":1761870124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011005519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S2152265011005519"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.10.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations in the Management of Elderly Patients With Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}